Predictive Oncology Inc.
POAI
$0.99
-$0.0094-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.72% | -28.11% | -46.39% | -17.39% | 4.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.72% | -28.11% | -46.39% | -17.39% | 4.22% |
| Cost of Revenue | 31.37% | 6.99% | 15.61% | -4.88% | 1.18% |
| Gross Profit | -31.83% | -47.77% | -72.98% | -24.11% | 5.93% |
| SG&A Expenses | -25.05% | -16.58% | -20.58% | -20.98% | -13.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.04% | -15.59% | -19.40% | -20.48% | -12.65% |
| Operating Income | 24.55% | 13.93% | 16.09% | 20.78% | 14.22% |
| Income Before Tax | 25.53% | 14.95% | 33.25% | 35.38% | 48.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.53% | 14.95% | 33.25% | 35.38% | 48.71% |
| Earnings from Discontinued Operations | 33.19% | -70.84% | -369.57% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.33% | 9.44% | 24.18% | 27.34% | 42.68% |
| EBIT | 24.55% | 13.93% | 16.09% | 20.78% | 14.22% |
| EBITDA | 24.27% | 11.88% | 12.46% | 17.67% | 9.70% |
| EPS Basic | 49.94% | 27.41% | 34.06% | 31.29% | 46.21% |
| Normalized Basic EPS | 48.30% | 30.75% | 25.48% | 24.60% | 16.77% |
| EPS Diluted | 49.96% | 27.33% | 34.00% | 31.29% | 46.20% |
| Normalized Diluted EPS | 48.30% | 30.75% | 25.48% | 24.60% | 16.77% |
| Average Basic Shares Outstanding | 54.08% | 35.75% | 20.43% | 6.33% | 4.80% |
| Average Diluted Shares Outstanding | 54.08% | 35.75% | 20.43% | 6.33% | 4.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |